Therapeutic effect of saffron extract in patients with chronic schizophrenia
Phase 3
Recruiting
- Conditions
- schizophernia.Schizophrenia
- Registration Number
- IRCT20210525051404N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Schizophrenia according to the DSM-V-TR criteria
stable symptoms
Age between 18 and 65 years
Exclusion Criteria
General medical problems (including coronary artery disease, metabolic syndrome, and neurological diseases)
Drug abuse
Taking antiplatelet drugs
Taking herbal medicines
Sensitivity to saffron
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method egative symptoms of schizophernia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.;Positive symptoms of schizophrenia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.;General symptoms of schizophrenia. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Positive and Negative Syndrome Scale.
- Secondary Outcome Measures
Name Time Method Symptoms of anxiety. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Hamilton Anxiety Scale.;Symptoms of depression. Timepoint: Beginning of research and end of research (fourth week). Method of measurement: Hamilton Depression Scale.